Rubius' roller coaster ride set to accelerate with first clinical results

After a rocky start as a public company, Rubius Therapeutics is hoping to enter 2020 on a smoother path, as the biotech prepares to soon release the first clinical data from its new drug platform.

In July, the Cambridge-based company went public with a lofty market value above $1.5 billion despite lacking revenue or any product candidates in human testing.